Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous beagle

Journal of Ocular Pharmacology and Therapeutics

Volumn 18, Issue 6, 2002, Pages 525-534

  Gelatt, Kirk N ^a   Mackay, Edward O ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; METHYLCELLULOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOG; DRUG DOSE REGIMEN; DRUG INSTILLATION; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; MIOSIS; NONHUMAN; PUPIL; TONOMETRY;

EID: 0036907857     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076802321021072     Document Type: Article

References (46)

1. Higginbotham EJ. Editorial: Will latanoprost be the 'wonder' drug of the '90s for the treatment of glaucoma? Arch. Ophthalmol. 114:998-999, 1996.
2. Wyse TB, Talluto DM, Krupin T, Rosenberg LF, and Ruderman JM. Topical prostaglandins for glaucoma therapy. J. Glaucoma. 6:180-187, 1997.
3. Bito LZ. Prostaglandins: A new approach to glaucoma management with a new intriguing side effect. Surv. Ophthalmol. 41 (Supplement 2): S1-S14, 1997.
4. Sponsel WE, Mensah J, Kiel JW, Remky A, Trigo, Baca W, and Friberg T. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye. Am. J. Ophthalmol. 130:151-159, 2000.
5. Alm A, and Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmol. 102:1743-1752, 1995.
6. Camras CB, Alm A, Watson P, and Stjemschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Ophthalmol. 103:1916-1924, 1996.
7. Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, and Ritch R. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am. J. Ophthalmol. 124:279-286, 1997.
8. Susanna R, Giampani J, Borges AS, Vessani RM, and Jordao MLS. A double-masked randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmol. 108:259-263, 2001.
9. Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, and Davis AA. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am. J. Ophthalmol. 132:860-868, 2001.
10. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, and Davis AA. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:472-484, 2001.
11. Goldberg I, Vaz JC, Jacobsen JE, Nordmann JP, Trost E, and Sullivan EK. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 10:414-422, 2001.
12. Hellberg MR, Sallee VL, Mclaughlin MA, Sharif NA, DeSantis L, Dean TR, and Zinke PW. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J. Ocular Pharm. and Therap. 17:421-432, 2001.
13. Gandollfi S, Simmons ST, Sturm R, Chen K, and Van Denburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Therapy 18:110-121, 2001.
14. Laibovitz RA, VanDenburgh AM, Felix C, Batoosingh A, Rosenthal A, and Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: Dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch. Ophthalmol. 119:994-1000, 2001.
15. Sherwood M, and Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. Suppl 4:S361-368, 2001.
16. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, and Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. Surv. Ophthalmol. Suppl 4:S353-360, 2001.
17. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol. Suppl 4: S347-351, 2001.
18. Brandt JD, VanDenburgh AM, Chen K, and Witcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmol. 108:1023-1031, 2001.
19. Woodward DF, Krauss AH, and Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. Suppl 4:S337-345, 2001.
20. Weinreb RN. Editorial: Uveoscleral outflow: The other outflow pathway. J. Glaucoma 9:343-345, 2000.
21. Lee P, Podos SM, and Severin C. Effect of prostaglandin F2a on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol. Vis. Sci. 25:1087-1093, 1984.
22. Bito LZ, Camras CB, Gum GG, and Resul B. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals. In The Ocular Effects of Prostaglandins and other Eicosanoids, LZ Bito and J Stjemschantz, editors. Alan R Liss, New York, 1989; pp 349-368.
23. Bito LZ, Fraga A, Blanco J, and Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or Rhesus monkey eyes. Invest. Ophthalmol. Vis. Sci. 24:312-319, 1983.
24. Toris CB, Yablonski ME, Wang YL, and Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp. Eye Res. 61:649-657, 1995.
25. Poyer JF, Gabelt B, and Kaufman PL. The effect of topical PGF2a on uveoscleral outflow and outflow facility in the rabbit eye. Exp. Eye Res. 54:277-283, 1992.
26. 2α/pilocarpine interactions on IOP and accommodation in monkeys. Exp. Eye Res. 61:677-683, 1995.
27. 2α isopropyl ester on intraocular pressure in normotensive and glaucomatous canine eyes. J. Ocular Pharm. 7:107-116, 1991.
28. 4 on pupil size, intraocular pressure, and blood-aqueous barrier in dogs. Am. J. Vet. Res. 53:1302-1304, 1992.
29. 2α isopropyl ester versus Iloprost phenacyl ester in rabbit and Beagle eyes. Curr. Eye Res. 8:131-138, 1989.
30. Studer ME, Martin CL, and Stiles J. Effects of 0.005% latanoprost solution on intraocular pressure in healthy dogs and cats. Am. J. Vet. Res. 61:1220-1224, 2000.
31. Gelatt KN, and MacKay EO. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle. Vet. Ophthalmol. 4:283-288, 2001.
32. Gelatt KN, Gum GG, Williams LW, and Barrie KP. Uveoscleral flow of aqueous humor in the normal dog. Am. J. Vet. Res. 40:845-848, 1979.
33. Barrie KP, Gum GG, Samuelson DA, and Gelatt KN. Quantitation of uveoscleral outflow in normotensive and glaucomatous beagles by 3H-labeled dextran. Am. J. Vet. Res. 46:84-88, 1986.
34. Barrie KP, Gum GG, Samuelson DA, and Gelatt KN. Morphologic studies of uveoscleral outflow in normotensive and glaucomatous beagles with fluorescein-labeled dextran. Am. J. Vet. Res. 46:89-97, 1985.
35. SAS/STAT, guide for personal computers, Version 6ed, Cary, NC:SAS Institute, Inc.
36. Gelatt KN, Gum GG, Barrie KP, and Williams LW. Diurnal variations in intraocular pressure in normotensive and glaucomatous Beagles. Glaucoma 3:121-124, 1981.
37. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, and Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. 41:2566-2573, 2000.
38. Yoshitomi T, and Ito Y. Effects of indomethacin and prostaglandins on the dog iris sphincter and dilator muscles. Invest. Ophthalmol. Vis. Sci. 29:127-132, 1988.
39. Lu W, Okamura T, Bian K, Inatomi A, and Toda N. Prostaglandins involved in contractions by angiotension II and bradykinin of isolated dog sphincter pupillae. Brit. J. Pharm. 95:544-550, 1988.
40. Zhan GL, Toris CB, Camras CB, Wang YL, and Bito LZ. Prostaglandin-induced iris color darkening. Arch. Ophthalmol. 116:1065-1068, 1998.
41. Selen G, Stjernschantz J, and Resul B. Prostaglandin-induced iridal pigmentation in primates. Surv. Ophthalmol. 41 (supplement): S125-S 128, 1997.
42. Zhan GL, Toris CB, Camras CB, Wang YL, and Bito LZ. Prostaglandin-induced iris color darkening. Arch. Ophthalmol. 116:1065-1068, 1998.
43. Gwin RM, Gelatt KN, Gum GG, Williams LW, and Peiffer RL. The effect of topical pilocarpine on intraocular pressure and pupil size in the normotensive and glaucomatous Beagle. Invest. Ophthalmol. Vis. Sci. 16:1135-1142, 1977.
44. Gum GG, Gelatt KN, Gelatt JK, and Jones R. The effect of topical demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in normal beagles and beagles with inherited glaucoma. Am. J. Vet. Res. 54:287-293, 1993.
45. Gelatt KN, Larocca RD, Gelatt JK, Strubbe DT, and MacKay EO. Evaluation of multiple doses of 4% and 6% timolol and timolol combined with 2% pilocarpine in normotensive and glaucomatous beagles. Am. J. Vet. Res. 56:1325-1331, 1995.
46. King TC, Gum GG, and Gelatt KN. Evaluation of a topical carbonic anhydrase inhibitor (MK-927) in normotensive and glaucomatous beagles. Am. J. Vet. Res. 52:2067-2070, 1991.